- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03903302
Study Investigation Pharmacokinetics and Pharmacodynamics of CS1
A Single Center, Randomised Study to Investigate Pharmacokinetics of CS1, Safety and Tolerability and in Obese, Borderline Hypertensive But Otherwise Healthy and Medicine Free Subjects After Administration of Single and Multiple Doses
SAD study:
Eighteen subjects will be included in the SAD study (single dose) in 3 parallel arms, each with 6 subjects. The 3 arms will receive a single dose of one of the CS1 formulations I, II or III. The result of the pharmacokinetics analysis from the 6 first subjects is defined as SAD Pilot and will be used to evaluate the timing of PK sampling. Based on pharmacokinetic evaluations from all 18 subjects one of the formulations I (275 mg), II (276 mg) or III (276 mg) will be chosen to proceed into the MAD study. If none of the formulations show the desired PK properties the formulations may be re-dosed with a slightly different timing of the dose, i.e the IMP to be administered earlier or later during the evening.
MAD study:
Fifteen subjects will be included in a dose escalating study with 2 dose levels. The subjects will receive the lowest dose level (275 or 276 mg depending on the outcome of SAD) for the first 2 weeks before the dose is doubled (550 or 552 mg depending on the outcome of SAD) for the following 2 weeks.
Study Overview
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
-
Uppsala, Sweden, 75237
- CTC Clinical Trial Consultants AB
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Willing and able to give written informed consent for participation in the study
- Male and female subjects age ≥ 40 years, ≤ 75 years inclusive.
- BMI 27- 35 kg/m2
- PAI-1 levels minimum 15 kIE/L (applies only to the MAD study)
- Acceptable medical history, physical findings, vital signs, ECG and laboratory values at the time of screening, as judged by the Investigator. Subjects with stable hypertension with one or more antihypertensive drugs can be accepted as acceptable medical history.
- Male subjects who has not documented a vasectomy, must be willing to use condom from the date of dosing until three months after dosing of the IMP to prevent drug exposure of a partner and refrain from donating sperm and if they have a fertile partner, she must use contraceptive methods with a failure rate of < 1% to prevent pregnancy .
- The females must be of non-childbearing potential defined as pre-menopausal females with a documented tubal ligation or hysterectomy; or post-menopausal defined as 12 months of amenorrhea (simultaneous determination of follicle stimulating hormone 25-140 IU/l and estradiol < 200 pmol/l is confirmatory) -
Exclusion Criteria:
Diagnosis and main eligibility criteria
Inclusion criteria:
- Willing and able to give written informed consent for participation in the study
- Male and female subjects age ≥ 40 years, ≤ 75 years inclusive.
- BMI 27- 35 kg/m2
- PAI-1 levels minimum 15 kIE/L (applies only to the MAD study)
- Acceptable medical history, physical findings, vital signs, ECG and laboratory values at the time of screening, as judged by the Investigator. Subjects with stable hypertension with one or more antihypertensive drugs can be accepted as acceptable medical history.
- Male subjects who has not documented a vasectomy, must be willing to use condom from the date of dosing until three months after dosing of the IMP to prevent drug exposure of a partner and refrain from donating sperm and if they have a fertile partner, she must use contraceptive methods with a failure rate of < 1% to prevent pregnancy .
- The females must be of non-childbearing potential defined as pre-menopausal females with a documented tubal ligation or hysterectomy; or post-menopausal defined as 12 months of amenorrhea (simultaneous determination of follicle stimulating hormone 25-140 IU/l and estradiol < 200 pmol/l is confirmatory)
Exclusion criteria:
- History of any clinically significant disease or disorder which, in the opinion of the Investigator, may either put the subject at risk because of participation in the study, or influence the results or the subject's ability to participate in the study.
- Subjects with active or chronic liver disease or personal or familiar history of drug related severe hepatic dysfunction.
- Subjects with phorphyria.
- Subjects with Systemic lupus erytematosus (SLE)
- Subjects with TPK, APTT, INR levels which are significant outside the reference intervals as judged by the investigator.
- History of severe bleeding disease or thrombotic disease.
- Subjects on regular treatment with anticoagulant or antiplatelets drugs
- Subjects with significant cardiac disease.
- Subjects with significant pancreatic disease.
- Subjects with gastrointestinal problems/ diseases e.g. inflammatory bowel disease and irritable bowel syndrome
- Any clinically significant illness, medical/surgical procedure or trauma within four weeks of the first administration of IMP.
- Any planned major surgery within the duration of the study.
- Any positive result on screening for serum hepatitis B surface antigen, hepatitis C antibody and Human Immunodeficiency Virus (HIV).
After 10 minute supine rest at the time of screening, any vital signs values outside the following ranges:
- Systolic blood pressure > 160 mm Hg
- Diastolic blood pressure > 100 mm Hg
- Heart rate < 40 or > 90 beats per minute
- Prolonged QTcF (>450 ms), cardiac arrhythmias or any clinically significant abnormalities in the resting ECG at the time of screening, as judged by the Investigator.
- History of severe allergy/hypersensitivity or on-going allergy/hypersensitivity, as judged by the Investigator, or history of hypersensitivity to drugs with a similar chemical structure or class to valproate acid or any other ingredient of the investigational medicinal product.
- Administration of another new chemical entity (defined as a compound which has not been approved for marketing) or has participated in any other clinical study that included drug treatment with less than three months between administration of last dose and first dose of IMP in this study. Subjects consented and screened but not dosed in previous phase I studies are not excluded.
- Current smokers or users of nicotine products. Irregular use of nicotine (e.g. smoking, snuffing, chewing tobacco) less than three times per week is allowed before screening visit.
- Positive screen for drugs of abuse or alcohol at screening or on admission to the unit prior to administration of the IMP.
- Current or history of alcohol abuse and/or use of anabolic steroids or drugs of abuse.
- Intake of xanthine and/or taurine containing energy drinks within two days prior to screening.
- Plasma donation within one month of screening or blood donation (or corresponding blood loss) during the three months prior to screening.
Investigator considers the subject unlikely to comply with study procedures, restrictions and requirements.
-
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
ACTIVE_COMPARATOR: CS 1 I SAD
Single dose pharmacokinetics of CS1 I
|
Single and multiple dose evaluation of CS1
|
ACTIVE_COMPARATOR: CS 1 II SAD
Single dose pharmacokinetics of CS1 II
|
Single and multiple dose evaluation of CS1
|
ACTIVE_COMPARATOR: CS 1 III SAD
Single dose pharmacokinetics of CS1 III
|
Single and multiple dose evaluation of CS1
|
ACTIVE_COMPARATOR: CS 1 II MAD
Multiple dose pharmacokinetics of CS1 II
|
Single and multiple dose evaluation of CS1
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Pharmacokinetic of CS1 in plasma
Time Frame: up to four weeks
|
Plasma concentration of Valproate in plasma
|
up to four weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence of Treatment-Emergent Adverse Events
Time Frame: up to four weeks
|
Adverse event recording in free text
|
up to four weeks
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
change in bleeding time
Time Frame: four weeks
|
Differences in bleeding time (minutes)
|
four weeks
|
Change in plasma PAI-1 levels
Time Frame: four weeks
|
ng/mL
|
four weeks
|
Change in hs-CRP levels
Time Frame: four weeks
|
mg/L
|
four weeks
|
Change in platelet numbers
Time Frame: four weeks
|
number of platelets per microliter blood
|
four weeks
|
Change in fibrinogen levels
Time Frame: four weeks
|
g/L
|
four weeks
|
Change in PAP
Time Frame: four weeks
|
ng/ml
|
four weeks
|
Collaborators and Investigators
Sponsor
Investigators
- Study Chair: Niklas Bergh, PhD, Cereno Scientific AB
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Cardiovascular Diseases
- Vascular Diseases
- Embolism and Thrombosis
- Thrombosis
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Central Nervous System Depressants
- Enzyme Inhibitors
- Tranquilizing Agents
- Psychotropic Drugs
- GABA Agents
- Anticonvulsants
- Antimanic Agents
- Valproic Acid
Other Study ID Numbers
- CS1-001
- 2017-002140-32 (EUDRACT_NUMBER)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Thrombosis
-
Università degli Studi dell'InsubriaOttawa Hospital Research InstituteUnknownPortal Vein Thrombosis | Mesenteric Vein Thrombosis | Splenic Vein ThrombosisCanada, Italy
-
University of MaltaUniversità degli Studi dell'InsubriaRecruitingCerebral Vein Thrombosis | Renal Vein Thrombosis | Retinal Vein Thrombosis | Splanchnic Vein Thrombosis | Ovarian Vein ThrombosisThailand, Spain, United States, Italy, Slovenia, France, Israel, Canada, Malta, Netherlands
-
Capital Medical UniversityBeijing Municipal Science & Technology CommissionNot yet recruitingCerebral Venous Sinus Thrombosis | Deep Cerebral Vein Thrombosis | Cortical Vein Thrombosis
-
Academic and Community Cancer Research UnitedNational Cancer Institute (NCI)CompletedDeep Vein Thrombosis | Venous Thromboembolism | Pulmonary Embolism | Malignant Neoplasm | Portal Vein Thrombosis | Metastatic Malignant Neoplasm | Cerebral Vein Thrombosis | Renal Vein Thrombosis | Gonadal Thrombosis | Hepatic Thrombosis | Mesenteric Thrombosis | Splenic ThrombosisUnited States
-
University of AlbertaSanofi; Edmonton Civic Employees Research FundTerminatedPortal Vein Thrombosis | Splenic Vein ThrombosisCanada
-
Assiut UniversityNot yet recruitingPortal Vein Thrombosis
-
Azienda Ospedaliera Universitaria PoliclinicoCompletedDeep Vein ThrombosisItaly
-
University of OklahomaPfizerCompleted
-
Fondazione Policlinico Universitario Agostino Gemelli...RecruitingSplanchnic Vein ThrombosisItaly
-
University Hospital, GenevaSunnybrook Health Sciences CentreNot yet recruitingDeep Vein Thrombosis
Clinical Trials on CS1-Sodium Valproate
-
Cardiaccs ASEuropean CommissionEnrolling by invitationCardiac Disease | Myocardial DysfunctionNorway
-
Cereno Scientific ABAbbott; Worldwide Clinical TrialsAvailablePulmonary Arterial HypertensionSweden
-
National Cerebral and Cardiovascular CenterJuntendo University; Kyoto University; Kobe City General HospitalCompleted
-
iCell Gene TherapeuticsPeking University Shenzhen Hospital; iCAR Bio Therapeutics Ltd.; Chengdu Military...UnknownMultiple MyelomaChina
-
Zhejiang UniversityYake Biotechnology Ltd.Not yet recruitingRelapse Multiple MyelomaChina
-
CardiacSense Ltd.CompletedAtrium; FibrillationIsrael
-
University of BirminghamActive, not recruitingWolfram SyndromeFrance, United Kingdom, Poland, Spain
-
Celyad Oncology SANational Heart, Lung, and Blood Institute (NHLBI); Dana-Farber Cancer InstituteCompletedAcute Myeloid Leukemia | Multiple Myeloma | Myelodysplastic SyndromeUnited States
-
Xijing HospitalUnknownTraumatic Brain InjuryChina
-
Cereno Scientific ABWorldwide Clinical TrialsRecruitingPulmonary Arterial HypertensionSweden